Mycenax’s business development team will be at the 16th International Bio Technology (Biotech Japan 2017) and Intrphex Japan 2017. Biotech Japan will be held in Tokyo on June 28-30. As an Asia’s leading Bio, Pharma R&D exhibition and conference, it is serving for the global biotechnology industry. Through participating conference, Mycenax business development representatives are seeking to deepen network and partner with innovators in Japan and others around the world.
Japan is the world’s third-largest biotech market after the U.S. and China. It is also ranked second globally in terms of R&D spending in biotech industry. Japan is becoming the global R&D center of regenerative medicine; many large international regenerative medicine companies are taking the Japanese market as the priority in their overseas enlargement plans.
The Japanese pharmaceutical industry is following the global shift trend from chemical drugs to protein drugs. As the domestic capacity of protein drugs production is insufficient, Japanese drug companies are actively searching for CMO partners.
Mycenax booth No: W17-46